Rheumatology

MinuteCE®
Decoding ANCA-Associated Vasculitis (AAV): From Suspicion to Solution
0.75 credits 6 episodes
- Bernhard Hellmich, MD
- Andreas Kronbichler, MD
- Silke R. Brix, MD, MRCP, SCPR
0.75 credits 6 episodes
Call to Action: Utilizing Avacopan to Improve AAV Care
Call to Action: Utilizing Avacopan to Improve AAV Care
CME/CE
Call to Action: Utilizing Avacopan to Improve AAV Care
- Stephen McAdoo, MD
Incorporating Targeted Therapies in Treatment Planning for AAV
Incorporating Targeted Therapies in Treatment Planning for AAV
CME/CE
Incorporating Targeted Therapies in Treatment Planning for AAV
- David Jayne, MD
- Bernhard Hellmich, MD
Can We Do Better in IgAN?
Can We Do Better in IgAN?
CME/CE
Can We Do Better in IgAN?
- Jonathan Barratt, PhD
- Annette Bruchfeld, MD, PhD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
CME/CE
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
- Jonathan Barratt, PhD
- Donald E. Kohan, MD, PhD
Case-Based Management of AAV
Case-Based Management of AAV
CME/CE
Case-Based Management of AAV
- David Jayne, MD
- Annette Bruchfeld, MD, PhD
Updates in Glomerular Disease
Updates in Glomerular Disease
CME/CE
Updates in Glomerular Disease
- Jürgen Floege, MD
- Jonathan Barratt, PhD
- David Jayne, MD